Xuanzhu Biopharmaceutical Co., Ltd.

轩竹生物科技股份有限公司

02575.HK

Develops innovative pharmaceutical drugs in China, with a pipeline of over ten drug assets targeting digestive diseases, oncology and NASH, including three NDA-approved products; majority-owned by Sihuan Pharm.

Filings

The documents are on HKEXnews; we link to the originals.

Matters the filing discloses

From the company’s latest filing; open a kind of matter to see how other companies disclosed it.

• Customer concentration
• Supplier concentration
• Distribution model
• Pricing policy and price changes
• Outsourced production (OEM / contract manufacturing)
• Reliance on the controlling shareholder
• Cash burn and runway
• Inventory level and ageing
• Goodwill, intangibles and asset impairment
• Investments and fair-value assets
• Adverse change after the track record
• Non-recurring gains and losses
• Related-party transactions and balances
• Chapter 18A biotech